Skip to main content

Advertisement

Table 5 Parameter values that have been specified by locally fitting the vascular tumour growth model to experimental data extracted from [61]

From: Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data

Cell line Experimental group λ 1 c d β p K 0 RMSE FOO
  day−1 mg/day · mm3p · kg day−1 · mm−2 mm3p - mm3 mm3  
H226 (lung cancer cells) Control 0.1028 0.7264 0.0075 - - 208.6162 16.7273 2.57 · 10−1
Treatment 1 0.1028 0.3982 0.0075 1 4.9963 183.4523 22.2226 10−3
(1 mg/kg)
Treatment 2 0.1028 0.3214 0.0075 1 5.6544 118.7044 8.0860 1.12 · 10−4
(5 mg/kg)
Treatment 3 0.1028 0.1735 0.0075 1 5.6024 320.1562 21.1671 3.31 · 10−4
(25 mg/kg)
HSCC1 (head and neck cancer cells) Control 0.0444 3.3548 0.0198 - - 23.6087 10.2691 9.5 · 10−2
Treatment 1 0.0444 1.4969 0.0190 1 5.0006 38.9545 27.8009 1.2 · 10−3
(1 mg/kg)
Treatment 2 0.0444 1.4895 0.0190 1 6.0014 30.6914 27.8653 6.88 · 10−4
(5 mg/kg)
Treatment 3 0.0444 0.8864 0.0190 1 5.5002 46.0371 9.7061 7.65 · 10−5
(25 mg/kg)
  1. First-order optimality (FOO) is a measure of the closeness of the solution to the optimal